Downloads

  1. Structural Biology Wages War On HIV And The Pandemics Of Tomorrow 2/27/2026

    Imagine waking up to news of another outbreak — masks, lockdowns, lives upended. But what if we could stop the next one before it starts? 

  2. The Matchmaker Modality: Engineering Event-Driven Pharmacology With Induced Proximity 2/24/2026

    Induced proximity has evolved into a versatile platform with the potential to change drug discovery, but challenges still remain.

  3. A State Of Stress: Developing Therapeutics Rooted In Cell Behavior 2/24/2026

    We caught up with Yerem Yeghiazarians, CEO of Soley Therapeutics, to discuss how capturing the complexity of disease requires going beyond a single target.

  4. Beyond KRAS G12C: New Approaches For Drugging The Undruggable 2/20/2026

    RAS was considered among the holy grail of oncology targets, but over the past decade, this has started to change. A second wave is making its way through R&D to address current shortcomings.

  5. ASH 2025 Reveals Strategic Implications For AML Drug Development 2/20/2026

    For treating acute myeloid leukemia, Revuforj and Komzifti draw frontline battle lines as Venclexta challenges the 7+3 paradigm, according to data shared at the recent ASH 2025 conference.

  6. Advances In Endometrial-Targeted Drug Delivery In Women's Health 2/19/2026

    Johns Hopkins investigators discuss gaps in women’s health research and how their work addresses endometrial dysfunction and infertility through precision nanomedicine.

  7. Thoughtful Supply Strategy Is No Longer Optional In Drug Development 2/16/2026

    In drug discovery and development, supply chain decisions are often treated as a downstream concern. In reality, supply strategy is a development decision from the very beginning.

  8. Building Inclusivity Into Early-Stage Preclinical Drug Discovery 2/13/2026

    Systematically reporting both ancestry and sex as standard biological variables may foster more representative and translationally relevant approaches to drug discovery.

  9. Rethinking Disease Modification Through Targeted Immunotherapy 2/11/2026

    As understanding of immune-driven disease deepens, therapies that selectively correct dysregulated inflammation have the potential to reshape treatment paradigms.

  10. New Approach Methods In Practice: Where Are We Today? 2/10/2026

    NAMs have moved beyond a technological promise, but now the current challenge is to operationalize their adoption.